Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for ImmunityBio (IBRX) over the last 10 years, with Q3 2025 value amounting to $3.4 million.

  • ImmunityBio's Depreciation and Depletion fell 1282.05% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.7 million, marking a year-over-year decrease of 1383.65%. This contributed to the annual value of $15.5 million for FY2024, which is 606.06% down from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Depreciation and Depletion is $3.4 million, which was down 1282.05% from $3.4 million recorded in Q2 2025.
  • ImmunityBio's 5-year Depreciation and Depletion high stood at $4.6 million for Q4 2022, and its period low was $3.3 million during Q1 2025.
  • For the 5-year period, ImmunityBio's Depreciation and Depletion averaged around $3.9 million, with its median value being $3.9 million (2022).
  • Data for ImmunityBio's Depreciation and Depletion shows a peak YoY increase of 7391.3% (in 2021) and a maximum YoY decrease of 3793.1% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows ImmunityBio's Depreciation and Depletion stood at $3.6 million in 2021, then increased by 27.78% to $4.6 million in 2022, then fell by 10.87% to $4.1 million in 2023, then decreased by 12.2% to $3.6 million in 2024, then fell by 5.56% to $3.4 million in 2025.
  • Its Depreciation and Depletion was $3.4 million in Q3 2025, compared to $3.4 million in Q2 2025 and $3.3 million in Q1 2025.